Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:IOVA NASDAQ:MESO NASDAQ:VALN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$8.70+0.1%$9.00$7.21▼$20.46$2.01B0.723.41 million shs3.19 million shsIOVAIovance Biotherapeutics$4.25-4.4%$3.83$1.66▼$5.63$1.98B0.7412.93 million shs15.58 million shsMESOMesoblast$15.55+1.1%$14.95$10.32▼$21.50$1.99B2.05167,357 shs149,684 shsVALNValneva$5.23-3.1%$5.66$5.06▼$12.25$512.38M1.7525,845 shs6,963 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+0.12%+3.33%+5.58%+4.95%-51.26%IOVAIovance Biotherapeutics-4.37%+8.04%+3.31%+15.07%+125.85%MESOMesoblast+1.11%+11.31%+2.30%+4.64%+48.80%VALNValneva-3.15%-2.24%-11.80%-17.25%-6.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$8.70+0.1%$9.00$7.21▼$20.46$2.01B0.723.41 million shs3.19 million shsIOVAIovance Biotherapeutics$4.25-4.4%$3.83$1.66▼$5.63$1.98B0.7412.93 million shs15.58 million shsMESOMesoblast$15.55+1.1%$14.95$10.32▼$21.50$1.99B2.05167,357 shs149,684 shsVALNValneva$5.23-3.1%$5.66$5.06▼$12.25$512.38M1.7525,845 shs6,963 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+0.12%+3.33%+5.58%+4.95%-51.26%IOVAIovance Biotherapeutics-4.37%+8.04%+3.31%+15.07%+125.85%MESOMesoblast+1.11%+11.31%+2.30%+4.64%+48.80%VALNValneva-3.15%-2.24%-11.80%-17.25%-6.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 2.33Hold$19.67126.05% UpsideIOVAIovance Biotherapeutics 2.30Hold$8.4398.51% UpsideMESOMesoblast 2.33HoldN/AN/AVALNValneva 2.20Hold$11.98128.97% UpsideCurrent Analyst Ratings BreakdownLatest VALN, ADMA, MESO, and IOVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026ADMAADMA Biologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)6/18/2026VALNValneva Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/10/2026ADMAADMA Biologics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy ➝ Outperform$21.006/10/2026ADMAADMA Biologics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy$21.005/26/2026ADMAADMA Biologics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/7/2026ADMAADMA Biologics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.00 ➝ $18.005/7/2026ADMAADMA Biologics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$24.00 ➝ $20.005/7/2026IOVAIovance Biotherapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $14.004/27/2026ADMAADMA Biologics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/22/2026VALNValneva The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral ➝ Sell$4.904/21/2026MESOMesoblast Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$510.17M3.95$0.66 per share13.28$2.01 per share4.33IOVAIovance Biotherapeutics$263.50M7.19N/AN/A$1.76 per share2.41MESOMesoblast$17.20M117.04N/AN/A$4.67 per share3.33VALNValneva$197.56M2.51N/AN/A$1.39 per share3.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$146.93M$0.6812.799.26N/A32.43%39.98%28.08%8/5/2026 (Estimated)IOVAIovance Biotherapeutics-$390.98M-$0.95N/AN/AN/A-123.92%-50.17%-38.77%8/6/2026 (Estimated)MESOMesoblast-$102.14M-$0.54N/AN/AN/AN/AN/AN/A9/2/2026 (Estimated)VALNValneva-$130.33M-$1.87N/A2.77N/A-88.87%-107.63%-33.02%8/11/2026 (Estimated)Latest VALN, ADMA, MESO, and IOVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026VALNValneva-$0.1485-$0.42-$0.2715-$0.42$54.69 million$36.16 million5/7/2026Q1 2026IOVAIovance Biotherapeutics-$0.19-$0.19N/A-$0.19$77.84 million$71.43 million5/6/2026Q1 2026ADMAADMA Biologics$0.1933$0.19-$0.0033$0.19$139.98 million$114.49 million3/31/2026Q4 2025VALNValnevaN/A-$0.42N/A-$0.42N/A$35.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.516.953.93IOVAIovance BiotherapeuticsN/A3.603.15MESOMesoblast0.101.581.41VALNValneva2.142.141.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%IOVAIovance Biotherapeutics77.03%MESOMesoblast1.43%VALNValneva11.39%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.90%IOVAIovance Biotherapeutics7.80%MESOMesoblast18.80%VALNValneva14.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530231.77 million222.73 millionOptionableIOVAIovance Biotherapeutics500446.50 million411.68 millionOptionableMESOMesoblast80129.46 million105.12 millionOptionableVALNValneva70094.89 million80.74 millionNot OptionableVALN, ADMA, MESO, and IOVA HeadlinesRecent News About These CompaniesValneva Announces Availability of Documentation for its Annual General MeetingJune 4, 2026 | globenewswire.comVALNEVA:Declaration of shares and voting rights - Status as of May 31, 2026June 3, 2026 | finance.yahoo.comValneva annonce sa participation à des conférences investisseurs aux États-Unis et en EuropeMay 28, 2026 | globenewswire.comValneva to Participate at U.S. and European Investor Conferences in JuneMay 28, 2026 | globenewswire.comValneva SE 2026 Q1 - Results - Earnings Call PresentationMay 16, 2026 | seekingalpha.comValneva SE (VALN) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comValneva SE (INRLF) Q1 2026 Earnings Call Highlights: Promising Vaccine Developments Amid ...May 13, 2026 | uk.finance.yahoo.comValneva to lay off up to 15% of workforce in face of ‘adverse trend’ in travel vaccinesMay 13, 2026 | fiercebiotech.comFValneva Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 13, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNMay 7, 2026 | prnewswire.comVALNEVA: Declaration of shares and voting rights - Status as of April 30, 2026 taking into account interim information as at May 5, 2026May 5, 2026 | globenewswire.comValneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026May 5, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNApril 30, 2026 | prnewswire.comValneva Announces the Successful Completion of an €84 million Reserved OfferingApril 30, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNApril 28, 2026 | globenewswire.comAs tick season drags longer, Pfizer hopes to release a Lyme disease vaccine in 2027April 27, 2026 | politifact.comPValneva's Commercial Crossroads: A Vaccine Maker's Pivotal YearApril 23, 2026 | aktiencheck.deAINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALNApril 21, 2026 | globenewswire.comA vaccine for Lyme disease could be on the horizonApril 20, 2026 | sciencenews.orgSGuggenheim Cuts PT on Valneva SE (VALN) to $11 From $13April 20, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026Will the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit?By Ryan Hasson | June 2, 2026Quantum Stocks Just Got a Lifeline—Who Benefits Most?By Nathan Reiff | May 26, 20263 Biotech Firms With Major Potential Catalysts in the Coming MonthsBy Nathan Reiff | June 21, 2026VALN, ADMA, MESO, and IOVA Company DescriptionsADMA Biologics NASDAQ:ADMA$8.70 +0.01 (+0.12%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$8.72 +0.02 (+0.26%) As of 05:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Iovance Biotherapeutics NASDAQ:IOVA$4.25 -0.19 (-4.37%) Closing price 06/24/2026 03:59 PM EasternExtended Trading$4.34 +0.09 (+2.10%) As of 05:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Mesoblast NASDAQ:MESO$15.55 +0.17 (+1.11%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$15.50 -0.04 (-0.29%) As of 06/24/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Valneva NASDAQ:VALN$5.23 -0.17 (-3.15%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$5.26 +0.03 (+0.57%) As of 04:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
